December 3, 2019

QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition.
The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.

The poster is being shown on Saturday, December 7, from 5:30 PM to 7:30 PM at Hall B, Level 2 of Orange County Convention Center:

“A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies”
by Srikumar Sahasranaman (Clinical Pharmacology, BeiGene USA, Inc.), Oleg Demin Jr (InSysBio), Dmitry Shchelokov (InSysBio), Veronika Musatova (InSysBio), Nageshwar Budha (Clinical Pharmacology, BeiGene USA, Inc.) and Ying Ou (Clinical Pharmacology, BeiGene USA, Inc.).

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

Share